Mineralys Therapeutics Reports New Data Of Analysis From Its Pivotal Phase 3 Launch-HTN Study

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related outcomes in comorbid conditions such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today the presentation of a new analysis from its pivotal Phase 3 Launch-HTN trial, showing that at Week 12, 46% of lorundrostat-treated participants achieved the AHA/ACC Guideline recommended office systolic blood pressure (SBP) target of <130 mmHg. These results were presented at the American Heart Association Hypertension Scientific Sessions 2026 (AHA-HTN), taking place October 7-11 in Arlington, VA.